Epigenetics Drugs and Diagnostic Technologies Market Challenges & Forecast

BrandessenceMarket Research is working on a new report title “Epigenetics Drugs and Diagnostic Technologies Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025.Growing prevalence of oncological and non-oncological conditions like respiratory diseases, alzheimer disease and growing R & D investments in the healthcare industries promotes the growth of global epigenetics drugs and diagnostic technologies market.

Epigenetics Drugs and Diagnostic Technologies Market is valued at USD 7.71 Billion in 2018 and expected to reach USD 27.13 Billion by 2025 with the CAGR of 19.68% over the forecast period.

Epigenetics is a study of heritable variations in gene expression; it is a trait change without genotype alteration. Epigenetic change is a normal and natural phenomenon but can also be affected by a variety of factors like age, environment or lifestyle and disease state.New and ongoing work continues to uncover the role of epigenetics in a variety of human disorders and fatal diseases. Many diseases are affected by epigenetic processes, including cancer, heart disease, diabetes and mental illnesses. Epigenetic therapy provides a potential way to directly influence those pathways.Epigenetic drugs and diagnostics are used in early stage cancer screening, as well as other pathological modifications in skin cells, liver cells, brain cells and others. Epigenetic test kits are used to diagnose diseases due to early-stage epigenetic changes and during therapy to verify the therapeutic efficacy. They work by involving modification-specific monoclonal antibodies, based on immunoprecipitation.Epigenetic drugs belong to a group of medications which are used to treat different cancers and other diseases like respiratory diseases, alzheimer disease. Those drugs fall into two groups which are methylation inhibitors of DNA and inhibitors of histone deacetylase. There are seven cancer care drugs have been licensed by the FDA. Also epigenetic drugs used in sensitization of chemotherapy, radiotherapy, and modulation of immune system.

The global epigenetics drugs and diagnostic technologies market is segmented on the basis of product, type of therapy, technology, application and region and country level. On the basis of product, the global epigenetics drugs and diagnostic technologies market is segmented into reagents, kits, instruments, enzymes and services. Based on type of therapy, the epigenetics drugs and diagnostic technologies market is classified into histone deacetylase (HDAC) inhibitors and DNA methyltransferase (DNMT) inhibitors. On the basis of technology, the global epigenetics drugs and diagnostic technologies market is segmented into DNA methylation, histone methylation, histone acetylation, large non-coding RNA, microRNA modification and chromatin structures.On the basis of application, the global epigenetics drugs and diagnostic technologies market is segmented into oncology and non-oncology.

The regions covered in global Epigenetics Drugs and Diagnostic Technologies Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, global Epigenetics Drugs and Diagnostic Technologies Marketsub divided in U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Get Full Report: @ https://brandessenceresearch.com/requestSample/PostId/1242

Key Players for Global Epigenetics Drugs and Diagnostic Technologies Market Reports –

Global Epigenetics Drugs and Diagnostic Technologies Marketreports cover prominent playersZymo research, CellCentric Ltd, Thermo Fisher Scientific, Abcam, Eisai Co. Ltd, Diagenode, Merck, Elli Lilly, Syndax Pharmaceuticals, Inc., Qiagen, Chroma Therapeutics Ltd, Novartis International AG, Oncolys Biopharma Inc., Sigma-Aldrich Corporation, Valirx Plc and others..

Recent News -

Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

News: On 29 May 2020,Eli Lilly and Company revealed that the U.S. Food and Drug Administration (FDA) has approved the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations of CYRAMZA ® (ramucirumab injection) in conjunction with erlotinib. The first and only FDA-approved anti-VEGFR / EGFR TKI combination therapy for metastatic EGFR-mutated NSCLC is CYRAMZA plus erlotinib. This approval is based on the efficacy and safety of the global, randomized, placebo-controlled Phase 3 RELAY trial. In the RELAY trial, CYRAMZA, VEGF receptor 2 antagonists, in combination with erlotinib, a globally approved EGFR-targeting tyrosine kinase inhibitor (TKI), demonstrated a statistically significant and clinically important increase in progression-free survival (PFS) as compared to placebo in combination. A significant breakthrough in the treatment of this disease is the approval of this new first-line metastatic EGFR-mutated non-small cell lung cancer regimen, which jointly inhibits the VEGFR and EGFR pathways. Now patients have multiple options for initial therapy that can delay the progression of disease considerably longer than erlotinib, which was our traditional standard.

Key Benefits for Epigenetics Drugs and Diagnostic Technologies Marketreports –

· Global Epigenetics Drugs and Diagnostic Technologies Marketreport covers in depth historical and forecast analysis.

· Global Epigenetics Drugs and Diagnostic Technologies Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

· Global Epigenetics Drugs and Diagnostic Technologies Market report helps to identify opportunities in market place.

· Global Epigenetics Drugs and Diagnostic Technologies Market report covers extensive analysis of emerging trends and competitive landscape.

Epigenetics Drugs and Diagnostic Technologies MarketSegmentation–

Epigenetics Drugs and Diagnostic Technologies Market:By Product

· Reagents

· Kits

· Instruments

· Enzymes

· Services

Epigenetics Drugs and Diagnostic Technologies Market: By Type of Therapy

· Histone Deacetylase (HDAC) Inhibitors

· DNA Methyltransferase (DNMT) Inhibitors

Epigenetics Drugs and Diagnostic Technologies Market: By Technology

· DNA Methylation

· Histone Methylation

· Histone Acetylation

· Large Non-Coding RNA

· MicroRNA Modification

· Chromatin Structures

Epigenetics Drugs and Diagnostic Technologies Market:By Application

· Oncology

· Non-Oncology

Epigenetics Drugs and Diagnostic Technologies Market: By Regional &Country Analysis

· North America

o U.S.

o Mexico

o Canada

· Europe

o UK

o France

o Germany

o Italy

· Asia Pacific

o China

o Japan

o India

o Southeast Asia

· South America

o Brazil,

o Argentina

o Columbia

· The Middle East and Africa

o GCC

o Africa

o Rest of Middle East and Africa

Get Sample Report: @ https://brandessenceresearch.com/healthcare/epigenetics-drugs-and-diagnostic-technologies-market-size

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Page updated

Google Sites

Report abuse